<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180730040640N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-09-30</date_registration>
      <primary_sponsor>Boushehr University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Topical Tranexamic Acid in endoscopic sinus surgery</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Topical Tranexamic Acid on Bleeding Reduction during Functional Endoscopic Sinus Surgery in choronic rhinosinousitis patient</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/32971</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Randomization description: For random allocation of participants (individuals), a gender-based minimization method and balanced blocks will be used, Blinding description: The present study is a double-blind clinical trial on 56 patients with chronic rhinosinusitis requiring sinus endoscopic surgery which will be held in Bushehr’s Hospital.Blindness will take place by random allocation by an operating room technician.For random allocation of individuals a gender-based minimization method is going to use in form of balanced blocks.the surgeon and the person assessing will get full blindness on the study , only the nurse who is supposed to perform mesh placing will be fully informed.</study_design>
      <phase>3</phase>
      <hc_freetext>Bleeding control and improvement of the quality of surgical field in sinus endoscopic surgery of  those who need surgery that did not respond to drug therapy..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: a group of 56 patients with chronic rhinosinusitis, requiring sinus endoscopic surgery was obtained. For preoperation patient , a mesh soaked in a mixture of phenylephrine 0.05 %vol. and transamic  acid at a dose of 15 mg / kg for 10 minutes will be placed in the nose(nasal cavity) of the patient by an operating room technician, then it will get extracted and operation(procedure) will begin.   Bleeding rate will measure according to the Boezaart grade scale and the surgeon's satisfaction is going to measure based on the Likert scale. Intervention 2: Control group: This group is consist of 56 patients with chronic rhinosinusitis, requiring surgical endoscopy of the sinus. In this group, a mesh soaked in a solution of 0.05%vol. of phenylephrine for 10 minutes will be placed in the nose(nasal cavity) of the patient by an operating room technician, then the mesh will get extracted and operation(procedure) begins.   Bleeding rate would measure according to the Boezaart grade scale and the surgeon's satisfaction will measure based on the Likert scale.Clinical practice with a control group, community based and pragmatic, double-blind, randomized.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
No.There is not a plan to make this available

When:
No.There is not a plan to make this available

To whom:
No.There is not a plan to make this available

Conditions:
No.There is not a plan to make this available

Where to obtain:
No.There is not a plan to make this available

How to obtain:
No.There is not a plan to make this available

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Allahkaram Akhlaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Units 16, Block 1, Fatemeh Zahra pension, Moallem square, Siraf Ave</address>
        <city>Boushehr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7517933755</zip>
        <telephone>+98 77 3484 3924</telephone>
        <email>Akhlaghidr@gmail.com</email>
        <affiliation>Boushehr University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Allahkaram Akhlaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Units 16, Block 1, Fatemeh Zahra pension, Moallem square, Siraf Ave</address>
        <city>Boushehr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7517933755</zip>
        <telephone>+98 77 3484 3924</telephone>
        <email>Akhlaghidr@gmail.com</email>
        <affiliation>Boushehr University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with chronic rhinosinusitis that don't not respond to drug therapy and require sinus surgery
The age of the participant(s) must be between 18 and 60 years old
The amount of hemoglobin of the participant should be above 10 g/dl
the amount of Bleeding time (BT), Prothrombin time (PT), Partial thromboplastin time (PTT), International normalized Ratio (INR) should be normal in participants.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Participants with cardiovascular disorders.
Participants who have coagulation disorders or who are taking anticoagulant medicines(drugs)
Participants with inherited coagulation disorders such as thrombophilia.
Participants with coagulation disorders history in the past.
Participants who have a history (record) of allergy to any drug(s) in the past.
Participants who have been suffering from renal deficiency in the past.
Participants with cirrhosis.
Participants with chronic diseases, such as diabetes and hypertension.
Participants who are pregnant.
participants with malignant nasal tumor.
Color blindness</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J32.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic sinusitis, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: a group of 56 patients with chronic rhinosinusitis, requiring sinus endoscopic surgery was obtained. For preoperation patient , a mesh soaked in a mixture of phenylephrine 0.05 %vol. and transamic  acid at a dose of 15 mg / kg for 10 minutes will be placed in the nose(nasal cavity) of the patient by an operating room technician, then it will get extracted and operation(procedure) will begin.   Bleeding rate will measure according to the Boezaart grade scale and the surgeon's satisfaction is going to measure based on the Likert scale.</i_keyword>
      <i_keyword>Control group: This group is consist of 56 patients with chronic rhinosinusitis, requiring surgical endoscopy of the sinus. In this group, a mesh soaked in a solution of 0.05%vol. of phenylephrine for 10 minutes will be placed in the nose(nasal cavity) of the patient by an operating room technician, then the mesh will get extracted and operation(procedure) begins.   Bleeding rate would measure according to the Boezaart grade scale and the surgeon's satisfaction will measure based on the Likert scale.Clinical practice with a control group, community based and pragmatic, double-blind, randomized</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding during surgery. Timepoint: At 15th, 30th and 45th minute after intervention. Method of measurement: The Boezaart measuring scale.</prim_outcome>
      <prim_outcome>Surgeon's satisfaction with quality of surgical field. Timepoint: At 15th, 30th and 45th minute after intervention. Method of measurement: Likert scale plan for satisfaction.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood pressure. Timepoint: every 15 minutes after start of surgery. Method of measurement: heart monitoring.</sec_outcome>
      <sec_outcome>Bleeding volume. Timepoint: every 15 minutes after start of surgery. Method of measurement: suction device.</sec_outcome>
      <sec_outcome>Pulse rate. Timepoint: every 15 minutes after start of surgery. Method of measurement: heart monitoring.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Boushehr University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-08-19</approval_date>
        <contact_name>Ethics comittee of Bushehr University of Medical Sciences</contact_name>
        <contact_address>Sabzabad Blvd, Salman Farsi street, Reishehr Bushehr Boushehr Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
